Latest Insights in NGS-based MRD Detection: Learnings from a Retrospective AML Cohort Study

MRD serves as a critical biomarker for relapse risk, prediction, and therapeutic response in AML.

• Current methods frequently lack the resolution and/or breadth of targets needed to identify key low-frequency mutations that drive recurrence.
• NGS-based MRD technologies offer a significant advantage, simultaneously providing lower detection limits and deeper genomic insights.

Sponsored by Oxford Gene Technology